TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22860693
Drug: Regular hypotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular hypotonic ORS (Na 60 mmol/L, glucose 78 mmol/L)
Study: 18822473
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (per os or parenteral)
Study: 10632230
Drug: Systemic behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic behavioral family therapy
Study: 1973583
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (4 mg) intravenously injected
Study: 18604074
Drug: Paracetamol syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol syrup
Study: 3911962
Drug: Paracetamol suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol suppositories
Study: 304522
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paracetamol with doxylaminsuccinate
Study: 23623339
Drug: 4 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mcg/kg dexmedetomidine
Study: 19154492
Drug: Non-invasive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive management (NIM) with immediate empirical antibiotic treatment (n = 34)
Study: 16749654
Drug: EZE/SIMVA 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA 10/20 mg
Study: 17451425
Drug: EZE/SIMVA 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA 10/40 mg
Study: 17451425
Drug: ATV 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV 20 mg
Study: 17451425
Drug: EZE/SIMVA 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA 10/20 mg, EZE/SIMVA 10/40 mg, ATV 20 mg
Study: 15070662
Drug: FLAG (Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAG (Fludarabine + ARA-C + G-CSF)
Study: 15070662
Drug: AG (ARA-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG (ARA-C + G-CSF)
Study: 11419672
Drug: Aminopenicillins at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminopenicillins at the correct dose
Study: 7500752
Drug: High-dose traction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose traction
Study: 9431610
Drug: Sham (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sham (low-dose) traction
Study: 8214532
Drug: Ropivacaine 1%
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1% (150 mg)
Study: 8214532
Drug: Bupivacaine 0.75%
Normalized name: BUPivacaine 0.75% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.75% (112.5 mg)
Study: 27580443
Drug: PSSIB (Palmar
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSSIB (Palmar Subcutaneous Single Injection Block)
Study: 27580443
Drug: DTIB (Dorsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIB (Dorsal 2 Injection Block)
Study: 25141962
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (indium gallium aluminum phosphorus (InGaAIP) laser operated at 660 nm) applied five days a week before each radiotherapy session.
Study: 20452927
Drug: Curriculum infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curriculum infusion (CI) in treatment classes
Study: 20452927
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no curriculum infusion)
Study: 16572301
Drug: Behavior observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior observation in training intervention agents
Study: 14517785
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg intravenous cyclosporine
Study: 14517785
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg intravenous cyclosporine
Study: 10379634
Drug: Isradipine SRO
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine SRO (2.5 mg)
Study: 10806134
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg)
Study: 10379634
Drug: Spirapril (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril (6 mg)
Study: 8884757
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vincamine twice daily
Study: 1647531
Drug: High compliance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High compliance enhancement group (wheat bran fiber supplement 18 g/day)
Study: 1647531
Drug: Medium compliance
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium compliance enhancement group (wheat bran fiber supplement 18 g/day)
Study: 1647531
Drug: Low compliance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low compliance enhancement group (wheat bran fiber supplement 18 g/day)
Study: 6195201
Drug: 1% gamma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% gamma benzene hexachloride (GBH) lotion applied for 6 hours
Study: 6195201
Drug: 1% gamma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% gamma benzene hexachloride (GBH) lotion applied for 12 to 24 hours
Study: 6195201
Drug: 1% gamma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% gamma benzene hexachloride (GBH) lotion applied for 2 hours
Study: 23314556
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (500 µg folic acid, 500 µg vitamin B12, 50 mg vitamin B6), 1200 IU vitamin D, and 456 mg calcium
Study: 19817285
Drug: Local block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local block therapy (Group B)
Study: 12732397
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl estradiol
Study: 12732397
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol
Study: 18989681
Drug: Parenteral testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral testosterone
Study: 9039199
Drug: Butenafine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butenafine 1% cream applied once daily for 4 weeks
Study: 30378087
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied once daily for 4 weeks
Study: 3594491
Drug: Adjuvant oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oral Bestatin treatment (30 mg daily for at least 1 year)
Study: 30782906
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg adrecizumab
Study: 30782906
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg adrecizumab
Study: 30782906
Drug: Adrecizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrecizumab (2 and 4 mg/kg)
Study: 21305612
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (ESC and DUL)
Study: 18223503
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (100 mL supplemented yogurt per day for 15 days)
Study: 18223503
Drug: Control yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control yogurt (100 mL unsupplemented yogurt per day for 15 days)
Study: 14562640
Drug: Unkei-to (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unkei-to (7.5 g/d)
Study: 3898291
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg, administered 3 times a week, subcutaneously for 6 weeks)
Study: 3898291
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered 3 times a week, subcutaneously for 6 weeks)
Study: 25407279
Drug: Lesogaberan 30
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 30 mg
Study: 25407279
Drug: Lesogaberan 90
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 90 mg
Study: 25407279
Drug: Lesogaberan 120
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 120 mg
Study: 25407279
Drug: Lesogaberan 240
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 240 mg
Study: 23302735
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg mifepristone once a day for 2 days + 200 µg misoprostol 48 hours later (G1 group)
Study: 23302735
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg mifepristone + 600 µg misoprostol 48 hours later (G2 group)
Study: 16095463
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml 3% dextran 60 solution
Study: 16095463
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml acetated Ringer's solution
Study: 12034106
Drug: Aerosol measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol measles and rubella (MR) vaccine
Study: 12034106
Drug: Subcutaneous measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous measles and rubella (MR) vaccine
Study: 7555467
Drug: Meloxicam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (7.5 mg/day)
Study: 7555467
Drug: Meloxicam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (15 mg/day)
Study: 2258250
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg/day)
Study: 2217669
Drug: Antibiotics before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics before the procedure
Study: 6093240
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotics)
Study: 28707431
Drug: T. foenum‐graecum
Approvals — FDA: no, EMA: no, PMDA: no
Description: T. foenum‐graecum de‐husked seed extract, 600 mg per day for 12 weeks
Study: 20079135
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 microg/kg bolus followed by continuous infusion of 0.1 microg x kg(‐1) x min(‐1)
Study: 20079135
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 microg/kg bolus followed by continuous infusion of 0.1 microg x kg(‐1) x min(‐1)
Study: 20079135
Drug: Sufentanil 0.1
Normalized name: bupivacaine-sufentanil 0.1%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.1 microg/kg bolus followed by continuous infusion of 0.01 microg x kg(‐1) x min(‐1)
Study: 15238028
Drug: Generation (participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generation (participants generated some study words, e.g., hot‐c__)
Study: 15238028
Drug: Reading (participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading (participants read other study words, e.g., hot‐cold)
Study: 12877377
Drug: Antibiotics (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (amoxicillin 750 mg x 2, doxycycline 100 mg x 2 or penicillin V 1500 mg x 2)
Study: 7784724
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (1 mg/kg) administered via regular endotracheal tube (group 1)
Study: 7784724
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (1 mg/kg) administered via suction-catheter deep endobronchially (group 2)
Study: 7784724
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (1 mg/kg) administered via EDGAR-tube (group 3)
Study: 7784724
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group 4) with regular endotracheal tube without lidocaine administration
Study: 2113848
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms levonorgestrel (L‐NOG)
Study: 31065703
Drug: GPM (GalliPro
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPM (GalliPro Max/B. subtilis, 500 g/ton)
Study: 31065703
Drug: GPT (GalliPro
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPT (GalliPro Tect/B. licheniformis, 500 g/ton)
Study: 28084890
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention group, median 1.8 h/week during adjuvant therapy (IQR 1.4-2.5)
Study: 23402718
Drug: Counterconditioning (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counterconditioning (CC) in context A (AAA-COUNTER-group)
Study: 23402718
Drug: Counterconditioning (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counterconditioning (CC) in context B (ABA-COUNTER-group)
Study: 23402718
Drug: Counterconditioning (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counterconditioning (CC)
Study: 22137072
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (weight of 121 kg)
Study: 22137072
Drug: Actual body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual body weight (ABW)-based dosing (no upper limit)
Study: 22137072
Drug: Ideal body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ideal body weight (IBW)-based dosing
Study: 11352416
Drug: DDAVP (Desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (Desmopressin Acetate) administered preoperatively
Study: 8044610
Drug: Chemotherapy (5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-fluorouracil, Adriamycin, and mitomycin)
Study: 21133981
Drug: Control (postponed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (postponed periodontal treatment)
Study: 17078443
Drug: Oral Benadryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Benadryl and Vitamin C plus local external application of 10% urea ointment
Study: 15217172
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing (ODD) of gentamicin 5 mg/kg
Study: 15217172
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing (TDD) of gentamicin 2.5 mg/kg
Study: 11089713
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (41%)
Study: 11089713
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (24%)
Study: 11089713
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics (17%)
Study: 11089713
Drug: Beta-blockers (10%)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (10%)
Study: 7911400
Drug: Lansoprazole 15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15, 30, or 60 mg/day for 4 and 8 weeks
Study: 2431908
Drug: meglumine diatrizoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: meglumine diatrizoate at 306 mgI/ml
Study: 2431908
Drug: iohexol at
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iohexol at 240 mgI/ml
Study: 29708818
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of LI73014F2
Study: 29708818
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of LI73014F2
Study: 27043774
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (enalapril + aliskiren)
Study: 24924842
Drug: Pulse ultrasound
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse ultrasound treatment for popliteal cyamella three times weekly for 8 weeks
Study: 24924842
Drug: Weekly shock
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly shock wave therapy for popliteal cyamella for the first 6 weeks
Study: 24924842
Drug: Isokinetic muscular
Normalized name: Orchis mascula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isokinetic muscular strengthening exercises three times weekly for 8 weeks
Study: 12464461
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P infusion
Study: 12464461
Drug: NaCl infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaCl infusion (Control)
Study: 10027502
Drug: Budesonide and
Normalized name: Budesonide and formoterol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and albuterol
Study: 10027502
Drug: Nedocromil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil and albuterol
Study: 10027502
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and albuterol
Study: 7560661
Drug: 12 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 micrograms formoterol solution
Study: 7560661
Drug: 24 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 micrograms formoterol solution
Study: 7560661
Drug: 12 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 micrograms formoterol suspension
Study: 7560661
Drug: 24 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 micrograms formoterol suspension
Study: 1981218
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ACE inhibitors)
Study: 7000628
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate tablets
Study: 31479770
Drug: Acuros dose-to-medium
Normalized name: Ricinus medius oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acuros dose-to-medium (Dm,m)
Study: 31479770
Drug: Acuros dose-to-water
Normalized name: HYALURONIC ACID 0.2 g in 100 g TOPICAL GEL [GZE Watery Sun Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acuros dose-to-water (Dw,m)
Study: 27921252
Drug: Oxycodone 10
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10 mg controlled-release tablets
Study: 27921252
Drug: Oxycodone-Naloxone 10/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone-Naloxone 10/5 mg controlled-release tablets
Study: 27921252
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Oxycodone)
Study: 27921252
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Oxycodone-Naloxone)
Study: 24873806
Drug: Diluted vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted vasopressin injection
Study: 22825784
Drug: Lipocryolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipocryolysis treatment
Study: 9403278
Drug: Felodipine ER,
Normalized name: Felodipine ER, 5 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER, 10 mg once daily
Study: 9403278
Drug: Nifedipine SR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine SR, 20 mg twice daily
Study: 8427864
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (0.25‐0.5 units/kg per week s.c. given each evening) for 6 months
Study: 3315286
Drug: Low-dose metoclopramide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metoclopramide and chlorpromazine
Study: 3519233
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide
Study: 31845733
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise intervention (MG)
Study: 29510711
Drug: Primaquine anti-relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine anti-relapse treatment
Study: 27347563
Drug: Rosuvastatin calcium,
Normalized name: Rosuvastatin Calcium, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin calcium, 20 mg/d
Study: 22978103
Drug: Di'ao Xinxuekang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di'ao Xinxuekang Soft Capsule (DK)
Study: 17560883
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or antiarrhythmic agents)
Study: 15616068
Drug: Propofol (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (doses: 0, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4 mg/kg)
Study: 15616068
Drug: Propofol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (doses > or = 1.0 mg/kg)
Study: 15616068
Drug: Propofol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (doses not specified)
Study: 7536681
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no CSF therapy)
Study: 2201162
Drug: Topical terlipressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terlipressin gel
Study: 7030227
Drug: 1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% silver sulphadiazine ointment
Study: 28183565
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with phenylephrine infusion
Study: 22472037
Drug: 42 g
Normalized name: PETROLATUM 42 g in 100 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 g pistachios (RSG)
Study: 22472037
Drug: 70 g
Normalized name: alcohol .70 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g pistachios (HSG)
Study: 11391123
Drug: Remacemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide (150 mg twice daily, increasing to 400 mg twice daily)
Study: 9721393
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate scrub solution
Study: 3884410
Drug: Sulodexide (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (high-dose glycosaminoglycan)
Study: 25498055
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy with CsA, everolimus twice daily and steroids (group A)